Streptococcus pneumoniae: Epidemiology, Risk Factors, and Clinical Features

ABSTRACT

Streptococcus pneumoniae is the most common cause of both pneumonia overall and fatal pneumonia. Antibiotic resistance has developed worldwide and is most frequent in pneumococcal serotypes that are most prevalent in children (types/groups 6, 14, 19, and 23). The incidence of pneumococcal disease is the highest in children < 2 years of age and in adults > 65 years of age. Other important risk factors are chronic heart and lung disease, cigarette smoking, and asplenia. A 23-valent capsular polysaccharide vaccine and a heptavalent protein-polysaccharide conjugate vaccine are currently available. The latter is specially designed for pediatric use because small children respond poorly to polysaccharide antigens. Both vaccines are efficacious in prevention of invasive pneumococcal disease.

The clinical presentation of pneumococcal pneumonia is variable, and neither clinical features nor laboratory or radiographic findings can reliably predict the etiology of pneumonia. Blood culture is the most important tool for establishing a definitive diagnosis, but Gram's stains and sputum culture are also of value in skilled hands. A recently developed urinary antigen test may provide a rapid diagnosis of pneumococcal pneumonia in adults. Penicillin (penicillin G/amoxicillin) remains the drug of choice for strains that are fully sensitive or have a moderately decreased susceptibility to penicillin, whereas cefotaxime and ceftriaxone are the first-line alternatives in cases with higher levels of resistance.

Pneumococcal pneumonia - epidemiology - prevention - treatment

REFERENCES

• 1 Austrian R. Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention.  Rev Infect Dis. 1981;  3(suppl 3) S1-17
• 2 Austrian R. The pneumococcus at the millennium: not down, not out.  J Infect Dis. 1999;  179(suppl 2) S338-S341
• 3 Monto A S. Acute respiratory infection in children of developing countries: challenge of the 1990s.  Rev Infect Dis. 1989;  11 498-505
• 4 Heffron R. Pneumonia: with special reference to pneumococcus lobar pneumonia. A Commonwealth Fund book. Cambridge, MA; The Commonwealth Fund 1939 reprinted by Harvard University Press 1979
• 5 Kalin M, Lindberg A A. Diagnosis of pneumococcal pneumonia: a comparison between microscopic examination of expectorate, antigen detection and cultural procedures.  Scand J Infect Dis. 1983;  15 247-255
• 6 Burman L A, Norrby R, Trollfors B. Invasive pneumococcal infections: incidence, predisposing factors, and prognosis.  Rev Infect Dis. 1985;  7 133-142
• 7 Örtqvist A, Hedlund J, Grillner L et al.. Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalization.  Eur Respir J. 1990;  3 1105-1113
• 8 Fang G D, Fine M, Orloff J et al.. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases.  Medicine (Baltimore). 1990;  69 307-316
• 9 Ruiz-Gonzalez A, Falguera M, Nogues A, Rubio-Caballero M. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia.  Am J Med. 1999;  106 385-390
• 10 Jokinen C, Heiskanen L, Juvonen H et al.. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland.  Am J Epidemiol. 1993;  137 977-988
• 11 Scott J A, Hall A J, Dagan R et al.. Serogroup-specific epidemiology of Streptococcus pneumoniae: associations with age, sex, and geography in 7000 episodes of invasive disease.  Clin Infect Dis. 1996;  22 973-981
• 12 Marrie T J. Pneumococcal pneumonia: epidemiology and clinical features.  Semin Respir Infect. 1999;  14 227-236
• 13 Gessner B D, Ussery X T, Parkinson A J, Breiman R F. Risk factors for invasive disease caused by Streptococcus pneumoniae among Alaska native children younger than two years of age.  Pediatr Infect Dis J. 1995;  14 123-128
• 14 Takala A K, Jero J, Kela E, Ronnberg P R, Koskenniemi E, Eskola J. Risk factors for primary invasive pneumococcal disease among children in Finland.  JAMA. 1995;  273 859-864
• 15 Davidson M, Schraer C D, Parkinson A J et al.. Invasive pneumococcal disease in an Alaska native population, 1980 through 1986.  JAMA. 1989;  261 715-718
• 16 Breiman R F, Spika J S, Navarro V J, Darden P M, Darby C P. Pneumococcal bacteremia in Charleston County, South Carolina: a decade later.  Arch Intern Med. 1990;  150 1401-1405
• 17 Magnus T, Andersen B M. Serotypes and resistance patterns of Streptococcus pneumoniae causing systemic disease in northern Norway.  Eur J Clin Microbiol Infect Dis. 1995;  14 229-234
• 18 Hedlund J, Svenson S B, Kalin M et al.. Incidence, capsular types, and antibiotic susceptibility of invasive Streptococcus pneumoniae in Sweden.  Clin Infect Dis. 1995;  21 948-953
• 19 Nielsen S V, Henrichsen J. Incidence of invasive pneumococcal disease and distribution of capsular types of pneumococci in Denmark, 1989-94.  Epidemiol Infect. 1996;  117 411-416
• 20 Mufson M A, Stanek R J. Epidemiology of invasive Streptococcus pneumoniae infections and vaccine implications among children in a West Virginia community, 1978-2003.  Pediatr Infect Dis J. 2004;  23 779-781
• 21 O'Brien K L, Walters M I, Sellman J et al.. Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection.  Clin Infect Dis. 2000;  30 784-789
• 22 Madhi S A, Klugman K P. A role for Streptococcus pneumoniae in virus-associated pneumonia.  Nat Med. 2004;  10 811-813
• 23 Hodges R G, MacLeod C M. Epidemic pneumococcal pneumonia V: final consideration of the factors underlying the epidemic.  Am J Hyg. 1946;  44 237-243
• 24 Musher D M, Groover J E, Reichler M R et al.. Emergence of antibody to capsular polysaccharides of Streptococcus pneumoniae during outbreaks of pneumonia: association with nasopharyngeal colonization.  Clin Infect Dis. 1997;  24 441-446
• 25 Kalin M. Pneumococcal serotypes and their clinical relevance.  Thorax. 1998;  53 159-162
• 26 van Dam J E, Fleer A, Snippe H. Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.  Antonie Van Leeuwenhoek. 1990;  58 1-47
• 27 Dillard J P, Vandersea M W, Yother J. Characterization of the cassette containing genes for type 3 capsular polysaccharide biosynthesis in Streptococcus pneumoniae .  J Exp Med. 1995;  181 973-983
• 28 Garcia E, Arrecubieta C, Munoz R, Mollerach M, Lopez R. A functional analysis of the Streptococcus pneumoniae genes involved in the synthesis of type 1 and type 3 capsular polysaccharides.  Microb Drug Resist. 1997;  3 73-88
• 29 Coffey T J, Enright M C, Daniels M et al.. Recombinational exchanges at the capsular polysaccharide biosynthetic locus lead to frequent serotype changes among natural isolates of Streptococcus pneumoniae .  Mol Microbiol. 1998;  27 73-83
• 30 Hermans P W, Sluijter M, Dejsirilert S et al.. Molecular epidemiology of drug-resistant pneumococci: toward an international approach.  Microb Drug Resist. 1997;  3 243-251
• 31 Nesin M, Ramirez M, Tomasz A. Capsular transformation of a multidrug-resistant Streptococcus pneumoniae in vivo.  J Infect Dis. 1998;  177 707-713
• 32 Nielsen S V, Henrichsen J. Capsular types of Streptococcus pneumoniae isolated from blood and CSF during 1982-1987.  Clin Infect Dis. 1992;  15 794-798
• 33 Verhaegen J, Glupczynski Y, Verbist L et al.. Capsular types and antibiotic susceptibility of pneumococci isolated from patients in Belgium with serious infections, 1980-1993.  Clin Infect Dis. 1995;  20 1339-1345
• 34 Robbins J B, Austrian R, Lee C J et al.. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups.  J Infect Dis. 1983;  148 1136-1159
• 35 Butler J C, Breiman R F, Campbell J F, Lipman H B, Broome C V, Facklam R R. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations.  JAMA. 1993;  270 1826-1831
• 36 Butler J C, Breiman R F, Lipman H B, Hofmann J, Facklam R R. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: implications for development of a conjugate vaccine.  J Infect Dis. 1995;  171 885-889
• 37 Peltola H, Booy R, Schmitt H J. What can children gain from pneumococcal conjugate vaccines?.  Eur J Pediatr. 2004;  163 509-516
• 38 Bruyn G A, Zegers B J, van Furth R. Mechanisms of host defense against infection with Streptococcus pneumoniae .  Clin Infect Dis. 1992;  14 251-262
• 39 Henriques Normark B, Kalin M, Örtqvist A et al.. Dynamics of penicillin-susceptible clones in invasive pneumococcal disease.  J Infect Dis. 2001;  184 861-869
• 40 Gonzalez B E, Hulten K G, Kaplan S L, Mason Jr E O. Clonality of Streptococcus pneumoniae serotype 1 isolates from pediatric patients in the United States.  J Clin Microbiol. 2004;  42 2810-2812
• 41 Watson D A, Musher D M, Verhoef J. Pneumococcal virulence factors and host immune responses to them.  Eur J Clin Microbiol Infect Dis. 1995;  14 479-490
• 42 Musher D M, Groover J E, Rowland J M et al.. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination.  Clin Infect Dis. 1993;  17 66-73
• 43 Hendley J O, Sande M A, Stewart P M, Gwaltney Jr J M. Spread of Streptococcus pneumoniae in families, I: Carriage rates and distribution of types.  J Infect Dis. 1975;  132 55-61
• 44 Pons J L, Mandement M N, Martin E et al.. Clonal and temporal patterns of nasopharyngeal penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae strains in children attending a day care center.  J Clin Microbiol. 1996;  34 3218-3222
• 45 Ekdahl K, Ahlinder I, Hansson H B et al.. Duration of nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae: experiences from the South Swedish Pneumococcal Intervention Project.  Clin Infect Dis. 1997;  25 1113-1117
• 46 Klugman K P, Friedland I R. Antibiotic-resistant pneumococci in pediatric disease.  Microb Drug Resist. 1995;  1 5-8
• 47 Tomasz A, Corso A, Severina E P et al.. Molecular epidemiologic characterization of penicillin-resistant Streptococcus pneumoniae invasive pediatric isolates recovered in six Latin-American countries: an overview. PAHO/Rockefeller University Workshop. Pan American Health Organization.  Microb Drug Resist. 1998;  4 195-207
• 48 Klugman K P, Madhi S A, Huebner R E, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection.  N Engl J Med. 2003;  349 1341-1348
• 49 Davidson M, Parkinson A J, Bulkow L R, Fitzgerald M A, Peters H V, Parks D J. The epidemiology of invasive pneumococcal disease in Alaska, 1986-1990: ethnic differences and opportunities for prevention.  J Infect Dis. 1994;  170 368-376
• 50 Sankilampi U, Herva E, Haikala R, Liimatainen O, Renkonen O V, Leinonen M. Epidemiology of invasive Streptococcus pneumoniae infections in adults in Finland.  Epidemiol Infect. 1997;  118 7-15
• 51 Kalin M, Örtqvist A, Almela M et al.. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries.  J Infect Dis. 2000;  182 840-847
• 52 Örtqvist A, Grepe A, Julander I, Kalin M. Bacteremic pneumococcal pneumonia in Sweden: clinical course and outcome and comparison with non-bacteremic pneumococcal and mycoplasmal pneumonias.  Scand J Infect Dis. 1988;  20 163-171
• 53 Austrian R, Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia.  Ann Intern Med. 1964;  60 759-776
• 54 Gransden W R, Eykyn S J, Phillips I. Pneumococcal bacteraemia: 325 episodes diagnosed at St Thomas's Hospital.  Br Med J (Clin Res Ed). 1985;  290 505-508
• 55 Watanakunakorn C, Bailey T A. Adult bacteremic pneumococcal pneumonia in a community teaching hospital, 1992-1996: a detailed analysis of 108 cases.  Arch Intern Med. 1997;  157 1965-1971
• 56 Lipsky B A, Boyko E J, Inui T S, Koepsell T D. Risk-factors for acquiring pneumococcal infections.  Arch Intern Med. 1986;  146 2179-2185
• 57 Nuorti J P, Butler J C, Farley M M et al.. Cigarette smoking and invasive pneumococcal disease.  N Engl J Med. 2000;  342 681-689
• 58 Bisharat N, Omari H, Lavi I, Raz R. Risk of infection and death among post-splenectomy patients.  J Infect. 2001;  43 182-186
• 59 Foss Abrahamsen A, Hoiby E A, Hannisdal E et al.. Systemic pneumococcal disease after staging splenectomy for Hodgkin's disease 1969-1980 without pneumococcal vaccine protection: a follow-up study 1994.  Eur J Haematol. 1997;  58 73-77
• 60 Brayton R G, Stokes P E, Schwartz M S, Louria D B. Effect of alcohol and various diseases on leukocyte mobilization, phagocytosis and intracellular bacterial killing.  N Engl J Med. 1970;  282 123-128
• 61 Jareo P W, Preheim L C, Gentry M J. Ethanol ingestion impairs neutrophil bactericidal mechanisms against Streptococcus pneumoniae .  Alcohol Clin Exp Res. 1996;  20 1646-1652
• 62 Perlino C A, Rimland D. Alcoholism, leukopenia, and pneumococcal sepsis.  Am Rev Respir Dis. 1985;  132 757-760
• 63 Janoff E N, O'Brien J, Thompson P et al.. Streptococcus pneumoniae colonization, bacteremia, and immune response among persons with human immunodeficiency virus infection.  J Infect Dis. 1993;  167 49-56
• 64 Hirschtick R E, Glassroth J, Jordan M C et al.. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group.  N Engl J Med. 1995;  333 845-851
• 65 Feldman C, Glatthaar M, Morar R et al.. Bacteremic pneumococcal pneumonia in HIV-seropositive and HIV-seronegative adults.  Chest. 1999;  116 107-114
• 66 Gilks C F, Ojoo S A, Ojoo J C et al.. Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya.  Lancet. 1996;  347 718-723
• 67 Peltola V T, McCullers J A. Respiratory viruses predisposing to bacterial infections: role of neuraminidase.  Pediatr Infect Dis J. 2004;  23(Suppl 1) S87-S97
• 68 Gross P A, Hermogenes A W, Sacks H S, Lau J, Levandowski R A. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature.  Ann Intern Med. 1995;  123 518-527
• 69 Nichol K L, Margolis K L, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community.  N Engl J Med. 1994;  331 778-784
• 70 Christenson B, Hedlund J, Lundbergh P, Örtqvist A. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons.  Eur Respir J. 2004;  23 363-368
• 71 Abraham-Van Parijs B. Review of pneumococcal conjugate vaccine in adults: implications on clinical development.  Vaccine. 2004;  22 1362-1371
• 72 Cornu C, Yzebe D, Leophonte P, Gaillat J, Boissel J P, Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials.  Vaccine. 2001;  19 4780-4790
• 73 Dear K, Holden J, Andrews R, Tatham D. Vaccines for preventing pneumococcal infection in adults.  Cochrane Database Syst Rev. 2003;  (4) CD000422
• 74 Fine M J, Smith M A, Carson C A et al.. Efficacy of pneumococcal vaccination in adults: a meta-analysis of randomized controlled trials.  Arch Intern Med. 1994;  154 2666-2677
• 75 Hutchison B G, Oxman A D, Shannon H S, Lloyd S, Altmayer C A, Thomas K. Clinical effectiveness of pneumococcal vaccine: meta-analysis.  Can Fam Physician. 1999;  45 2381-2393
• 76 Melegaro A, Edmunds W J. The 23-valent pneumococcal polysaccharide vaccine, I: Efficacy of PPV in the elderly: a comparison of meta-analyses.  Eur J Epidemiol. 2004;  19 353-363
• 77 Moore R A, Wiffen P J, Lipsky B A. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials.  BMC Fam Pract. 2000;  1 1
• 78 Watson L, Wilson B J, Waugh N. Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults.  Vaccine. 2002;  20 2166-2173
• 79 Austrian R, Douglas R M, Schiffman G et al.. Prevention of pneumococcal pneumonia by vaccination.  Trans Assoc Am Physicians. 1976;  89 184-194
• 80 Smit P, Oberholzer D, Hayden-Smith S, Koornhof H J, Hilleman M R. Protective efficacy of pneumococcal polysaccharide vaccines.  JAMA. 1977;  238 2613-2616
• 81 Honkanen P O, Keistinen T, Miettinen L et al.. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older.  Vaccine. 1999;  17 2493-2500
• 82 Örtqvist A, Hedlund J, Burman L A et al.. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group.  Lancet. 1998;  351 399-403
• 83 Shapiro E D, Berg A T, Austrian R et al.. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.  N Engl J Med. 1991;  325 1453-1460
• 84 Jackson L A, Neuzil K M, Yu O C et al.. Effectiveness of pneumococcal polysaccharide vaccine in older adults.  N Engl J Med. 2003;  348 1747-1755
• 85 Nichol K L, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease.  Arch Intern Med. 1999;  159 2437-2442
• 86 Hedlund J, Christenson B, Lundbergh P, Örtqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in elderly people: a 1-year follow-up.  Vaccine. 2003;  21 3906-3911
• 87 Breiman R F, Keller D W, Phelan M A et al.. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients.  Arch Intern Med. 2000;  160 2633-2638
• 88 French N, Nakiyingi J, Carpenter L M et al.. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial.  Lancet. 2000;  355 2106-2111
• 89 Lucero M, Dulalia V, Parreno R et al.. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of age.  Cochrane Database Syst Rev. 2004;  (4) CD004977
• 90 Black S B, Shinefield H R, Ling S et al.. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia.  Pediatr Infect Dis J. 2002;  21 810-815
• 91 Whitney C G, Farley M M, Hadler J et al.. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.  N Engl J Med. 2003;  348 1737-1746
• 92 Marfin A A, Sporrer J, Moore P S, Siefkin A D. Risk factors for adverse outcome in persons with pneumococcal pneumonia.  Chest. 1995;  107 457-462
• 93 Torres J M, Cardenas O, Vasquez A, Schlossberg D. Streptococcus pneumoniae bacteremia in a community hospital.  Chest. 1998;  113 387-390
• 94 Marrie T J. Pneumonia in the elderly.  Curr Opin Pulm Med. 1996;  2 192-197
• 95 Metlay J P, Schulz R, Li Y H et al.. Influence of age on symptoms at presentation in patients with community-acquired pneumonia.  Arch Intern Med. 1997;  157 1453-1459
• 96 Berk S L. Bacterial pneumonia in the elderly: the observations of Sir William Osler in retrospect.  J Am Geriatr Soc. 1984;  32 683-685
• 97 Brandenburg J A, Marrie T J, Coley C M et al.. Clinical presentation, processes and outcomes of care for patients with pneumococcal pneumonia.  J Gen Intern Med. 2000;  15 638-646
• 98 Mufson M A. Pneumococcal infections.  JAMA. 1981;  246 1942-1948
• 99 Tilghman R C, Finland M. Clinical significance of bacteremia in pneumococcic pneumonia.  Arch Intern Med. 1937;  59 602-619
• 100 Mufson M A, Kruss D M, Wasil R E, Metzger W I. Capsular types and outcome of bacteremic pneumococcal disease in the antibiotic era.  Arch Intern Med. 1974;  134 505-510
• 101 Örtqvist A, Kalin M, Julander I, Mufson M A. Deaths in bacteremic pneumococcal pneumonia: a comparison of two populations-Huntington, WVa, and Stockholm, Sweden.  Chest. 1993;  103 710-716
• 102 Murphy T F, Sethi S. Bacterial infection in chronic obstructive pulmonary disease.  Am Rev Respir Dis. 1992;  146 1067-1083
• 103 Kalin M. Bacteremic pneumococcal pneumonia: value of culture of nasopharyngeal specimens and examination of washed sputum specimens.  Eur J Clin Microbiol. 1982;  1 394-396
• 104 Krantz I, Alestig K, Trollfors B, Zackrisson G. The carrier state in pertussis.  Scand J Infect Dis. 1986;  18 121-123
• 105 Bartlett J G, Dowell S F, Mandell L A, File Jr T M, Musher D M, Fine M J. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.  Clin Infect Dis. 2000;  31 347-382
• 106 BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.  Thorax. 2001;  56(Suppl 4) IV1-64
• 107 Bohte R, Hermans J, van den Broek P J. Early recognition of Streptococcus pneumoniae in patients with community-acquired pneumonia.  Eur J Clin Microbiol Infect Dis. 1996;  15 201-205
• 108 Farr B M, Kaiser D L, Harrison B D, Connolly C K. Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. British Thoracic Society Pneumonia Research Subcommittee.  Thorax. 1989;  44 1031-1035
• 109 Musher D M. Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment.  Clin Infect Dis. 1992;  14 801-807
• 110 Ort S, Ryan J L, Barden G, D'Esopo N. Pneumococcal pneumonia in hospitalized patients: clinical and radiological presentations.  JAMA. 1983;  249 214-218
• 111 Örtqvist A, Hedlund J, Wretlind B, Carlstrom A, Kalin M. Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community-acquired pneumonia.  Scand J Infect Dis. 1995;  27 457-462
• 112 Light R W, Girard W M, Jenkinson S G, George R B. Parapneumonic effusions.  Am J Med. 1980;  69 507-512
• 113 Macfarlane J T, Miller A C, Roderick Smith W H, Morris A H, Rose D H. Comparative radiographic features of community acquired Legionnaires' disease, pneumococcal pneumonia, mycoplasma pneumonia, and psittacosis.  Thorax. 1984;  39 28-33
• 114 Shann F. Etiology of severe pneumonia in children in developing countries.  Pediatr Infect Dis. 1986;  5 247-252
• 115 Steinum O, Alestig K, Brorson J E. Culture from epipharynx of little value in bacterial pneumonia.  Scand J Infect Dis. 1987;  19 309-312
• 116 Davidson M, Tempest B, Palmer D L. Bacteriologic diagnosis of acute pneumonia: comparison of sputum, transtracheal aspirates, and lung aspirates.  JAMA. 1976;  235 158-163
• 117 Örtqvist A, Kalin M, Lejdeborn L, Lundberg B. Diagnostic fiberoptic bronchoscopy and protected brush culture in patients with community-acquired pneumonia.  Chest. 1990;  97 576-582
• 118 Garcia-Vazquez E, Marcos M A, Mensa J et al.. Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system.  Arch Intern Med. 2004;  164 1807-1811
• 119 Madison J M, Irwin R S. Expectorated sputum for community-acquired pneumonia: a sacred cow.  Arch Intern Med. 2004;  164 1725-1727
• 120 Musher D M. Gram stain and culture of sputum to diagnose bacterial pneumonia.  J Infect Dis. 1985;  152 1096
• 121 Marrie T J. Community-acquired pneumonia.  Clin Infect Dis. 1994;  18 501-513
• 122 Musher D M, Montoya R, Wanahita A. Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia.  Clin Infect Dis. 2004;  39 165-169
• 123 Farrington M, Rubenstein D. Antigen detection in pneumococcal pneumonia.  J Infect. 1991;  23 109-116
• 124 Venkatesan P, Macfarlane J T. Role of pneumococcal antigen in the diagnosis of pneumococcal pneumonia.  Thorax. 1992;  47 329-331
• 125 Murdoch D R, Laing R T, Mills G D et al.. Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia.  J Clin Microbiol. 2001;  39 3495-3498
• 126 Ishida T, Hashimoto T, Arita M, Tojo Y, Tachibana H, Jinnai M. A 3-year prospective study of a urinary antigen-detection test for Streptococcus pneumoniae in community-acquired pneumonia: utility and clinical impact on the reported etiology.  J Infect Chemother. 2004;  10 359-363
• 127 Dowell S F, Garman R L, Liu G, Levine O S, Yang Y H. Evaluation of Binax NOW, an assay for the detection of pneumococcal antigen in urine samples, performed among pediatric patients.  Clin Infect Dis. 2001;  32 824-825
• 128 Hedlund J, Örtqvist A, Kalin M. Nasopharyngeal culture in the pneumonia diagnosis.  Infection. 1990;  18 283-285
• 129 Taylor S N, Sanders C V. Unusual manifestations of invasive pneumococcal infection.  Am J Med. 1999;  107 (suppl 1A) 12S-27S
• 130 Pallares R, Gudiol F, Linares J et al.. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci.  N Engl J Med. 1987;  317 18-22
• 131 Kaplan S L, Mason Jr E O. Management of infections due to antibiotic-resistant Streptococcus pneumoniae .  Clin Microbiol Rev. 1998;  11 628-644
• 132 Garau J. Clinical perspectives on the management of community-acquired pneumonia.  Diagn Microbiol Infect Dis. 1996;  25 205-211
• 133 Chen D K, McGeer A, de Azavedo J C, Low D E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.  N Engl J Med. 1999;  341 233-239
• 134 Ho P L, Que T L, Tsang D N, Ng T K, Chow K H, Seto W H. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong.  Antimicrob Agents Chemother. 1999;  43 1310-1313
• 135 Davidson R, Cavalcanti R, Brunton J L et al.. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.  N Engl J Med. 2002;  346 747-750
• 136 Mandell L A, Marrie T J, Grossman R F, Chow A W, Hyland R H. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group.  Clin Infect Dis. 2000;  31 383-421
• 137 Niederman M S, Mandell L A, Anzueto A et al.. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention.  Am J Respir Crit Care Med. 2001;  163 1730-1754
• 138 Waterer G W, Somes G W, Wunderink R G. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia.  Arch Intern Med. 2001;  161 1837-1842
• 139 Martinez J A, Horcajada J P, Almela M et al.. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia.  Clin Infect Dis. 2003;  36 389-395
• 140 Baddour L M, Yu V L, Klugman K P et al.. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia.  Am J Respir Crit Care Med. 2004;  170 440-444